Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

Sionna Therapeutics is financially sound, with a healthy cash balance and minimal debt, allowing them to continue research and development efforts. Additionally, they have partnerships and collaborations with major pharmaceutical companies, providing further validation and potential resources for their drug development. Overall, Sionna Therapeutics has strong potential for success in the cystic fibrosis market, but investors should carefully monitor their progress and the competitive landscape.

Bears say

Sionna Therapeutics is a clinical-stage biotech company focused on developing novel therapies for cystic fibrosis (CF) patients. While the company has a promising drug in development, Alyftrek, its convenience compared to current CF treatments may not be enough to drive widespread adoption. Additionally, while positive data from their upcoming phase 2a study could de-risk and differentiate their other NBD1 targeting drug, SION-451, there may be challenges in translating the results to a clinical setting. Overall, while Sionna's preclinical data is compelling, there may be limitations in its application to real-world situations that could hinder the success of their therapies.

SION has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 10 analysts, SION has a Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.